New antibody drug enters human testing for serious kidney disease
NCT ID NCT07375758
Summary
This early-stage study aims to test the safety and effects of a new drug called MIL116, which is an antibody designed to target a protein involved in IgA nephropathy. It will first be given to healthy volunteers to check for safety, and then to patients with the kidney disease to see how their bodies process the drug and if it reduces certain disease markers. The goal is to gather information to see if this drug could help control the disease in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.